Fischer will join Fresenius Medical Care as CFO starting on Oct. 1, the company announced Monday. The Germany-based firm, which makes dialysis products and operates a network of clinics, has shuffled its leadership as parent company Fresenius plans to spin out the unit by the end of the year.
In December, Fresenius Medical Care promoted CFO Helen Giza to CEO. Giza will continue to serve as acting CFO for the company until Fischer starts this fall. When the company becomes a German stock corporation, Fischer will become a member of Fresenius Medical Care’s board.
“Martin Fischer has proven that he can successfully drive fundamental change in organizations. In our organizational transformation and turnaround management, we will benefit from his finance and healthcare expertise,” Giza said in a statement. “Martin will be an important contributor to the execution of our strategy in unlocking value as the leading kidney care company.”
Fischer joins the company after working as head of finance for the Siemens Healthineers Diagnostic Division. Before that, he held other operational and finance positions at Siemens.
He will be based in Bad Homburg, Germany, and will be responsible for Fresenius Medical Care’s global finance.
by Elise Reuter
Source: medtechdive.com
The United Arab Emirates (UAE) Ministry of Health and Prevention (MoHAP) has established a partnership with Novo Nordisk Pharma Gulf focusing on the creation of a national scientific guide for obesity management and weight control. The collaboration also aims to enhance public awareness of cardiovascular diseases and their complications.
Pharma giant Eli Lilly is teaming up with Haya Therapeutics in a $1bn deal to find multiple regulatory-genome-derived RNA-based drug targets, as it eyes up new targets in obesity. Under the deal, the companies will use Haya’s proprietary regulatory genome discovery platform to identify and validate long non-coding RNA (lncRNA) targets for developing potential treatments for obesity and related metabolic disorders.
The sale includes custom formulation and contract manufacturing capabilities for the nutrition market from the production facilities in New Jersey and Utah in the United States, and Tamaulipas, Mexico. Financial terms of the transaction were not disclosed.
